PRA Health Sciences Inc (NASDAQ:PRAH) – Investment analysts at William Blair increased their Q3 2019 earnings per share (EPS) estimates for PRA Health Sciences in a report released on Monday, May 13th. William Blair analyst J. Kreger now anticipates that the medical research company will earn $1.19 per share for the quarter, up from their previous forecast of $1.18. William Blair also issued estimates for PRA Health Sciences’ FY2020 earnings at $5.26 EPS.
PRA Health Sciences (NASDAQ:PRAH) last announced its quarterly earnings results on Wednesday, February 27th. The medical research company reported $1.21 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.18 by $0.03. The business had revenue of $729.65 million for the quarter, compared to analyst estimates of $750.67 million. PRA Health Sciences had a return on equity of 26.87% and a net margin of 5.50%.
Shares of PRAH stock opened at $88.10 on Thursday. The company has a current ratio of 0.90, a quick ratio of 0.90 and a debt-to-equity ratio of 0.97. The firm has a market capitalization of $5.86 billion, a P/E ratio of 22.42, a P/E/G ratio of 1.20 and a beta of 1.01. PRA Health Sciences has a one year low of $79.20 and a one year high of $121.98.
Institutional investors have recently bought and sold shares of the business. Cresset Asset Management LLC bought a new stake in shares of PRA Health Sciences during the first quarter worth $25,000. Motco raised its position in shares of PRA Health Sciences by 937.0% during the first quarter. Motco now owns 280 shares of the medical research company’s stock worth $31,000 after acquiring an additional 253 shares during the last quarter. Rockefeller Capital Management L.P. bought a new stake in shares of PRA Health Sciences during the first quarter worth $37,000. Financial Gravity Wealth Inc. bought a new stake in shares of PRA Health Sciences during the first quarter worth $53,000. Finally, Manchester Capital Management LLC bought a new stake in shares of PRA Health Sciences during the first quarter worth $57,000. 98.14% of the stock is currently owned by institutional investors.
About PRA Health Sciences
PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.
Featured Story: How to Invest in Growth Stocks
Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.